Phase 2 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis | Zendy

James D. Chalmers | Zendy; Charles Haworth | Zendy; Mark L. Metersky | Zendy; Michael R. Loebinger | Zendy; Francesco Blasi | Zendy; Oriol Sibila | Zendy; Anne E. O’Donnell | Zendy; Eugene J. Sullivan | Zendy; Kevin C. Mange | Zendy; Carlos FernándezPeña | Zendy; Jun Zou | Zendy; Charles L. Daley | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Phase 2 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis

Author(s) -

James D. Chalmers,

Charles Haworth,

Mark L. Metersky,

Michael R. Loebinger,

Francesco Blasi,

Oriol Sibila,

Anne E. O’Donnell,

Eugene J. Sullivan,

Kevin C. Mange,

Carlos FernándezPeña,

Jun Zou,

Charles L. Daley

Publication year - 2020

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa2021713

Subject(s) - bronchiectasis , neutrophil elastase , proteases , sputum , elastase , medicine , serine , gastroenterology , proteinase inhibitor , inflammation , enzyme , immunology , biochemistry , chemistry , lung , pathology , tuberculosis

Patients with bronchiectasis have frequent exacerbations that are thought to be related to neutrophilic inflammation. The activity and quantity of neutrophil serine proteases, including neutrophil elastase, are increased in the sputum of patients with bronchiectasis at baseline and increase further during exacerbations. Brensocatib (INS1007) is an oral reversible inhibitor of dipeptidyl peptidase 1 (DPP-1), an enzyme responsible for the activation of neutrophil serine proteases.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research